UPDATE ON THE CURRENT SHORTAGE ON THE ANTI-BODY DINUTUXIMAB (CH14.18/CH0) – PART OF IMMUNOTHERAPY TREATMENT
update Nov 2017
United Therapeutics, based in US, is now in a position to re-supply Australia and New Zealand with Dinutuximab having resolved previous supply issues. The product is available via IDIS Managed Access and would need to be requested by an oncologist.
There is also an alternative product, Dinutuximab Beta, marketed by EUSA Pharmaceuticals (in the UK), which is also available in Australia through a Managed Access Program but is very expensive. Applications to fund the supply of Dinutuximab beta can be made by individual oncologists with the support of their Hospital executive. Applications need to be made on an individual basis. The cost of this drug is high and ultimately the decision to fund will lie with each individual State’s Health Department.